Pharmacokinetic–pharmacodynamic modeling of the active components of Shenkang injection in rats with chronic renal failure and its protective effect on damaged renal cells
Biopharmaceutics & Drug Disposition · 2023
DOI: 10.1002/bdd.2377 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biopharmaceutics & Drug Disposition, 2023. Verfasst von Lin Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Emodin, Kidney Failure, Chronic, Drugs, Chinese Herbal, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Key scientific research Project of colleges and universities in Henan Province, Henan Province Science and Technology Research Project, Medical Science and Technology Project of Henan Province.
Abstract (Originalsprache)
The study aimed to explore the pharmacokinetic and pharmacodynamic alterations of the active components of Shenkang injection (i.e. hydroxy saffron yellow pigment A [HSYA], tanshinol, rheum emodin, and astragaloside IV) in rats with chronic renal failure (CRF), and establish a pharmacokinetic–pharmacodynamic model (PK‐PD model) in order to provide a scientific and theoretical basis for the rational clinical use of Shenkang injection. Sprague–Dawley (SD) rats were randomly divided into a normal group, model group, and Shenkang injection group. A rat model of CRF was induced by adenine gavage and then followed by drug administration via tail vein injection. Orbital blood was collected at different timepoints and the blood concentrations of the four active components were measured by UHPLC‐Q‐Orbitrap HRMS. Serum levels of creatinine (Scr), urea nitrogen (BUN), and uric acid (UA) were determined using an automatic biochemical analyzer. A PK‐PD model was established, and DAS 3.2.6 software was used for model fitting as well as statistical analysis. TGF‐β1 was utilized to induce normal rat kidney cells to construct a renal fibrosis model to investigate the protective effect of the pharmacological components on renal fibrosis. The pharmacokinetic analysis of hydroxy saffron yellow pigment A, tanshinol, rheum emodin, and astragaloside IV based on UHPLC‐Q‐Orbitrap HRMS was stable. The linear regression equations for the four active components were as follows: Y = 0.031X + 0.0091 ( R 2 = 0.9986) for hydroxy saffron yellow pigment A, Y = 0.0389X + 0.164 ( R 2 = 0.9979) for tanshinol, Y = 0.0257X + 0.0146 ( R 2 = 0.9973) for rheum emodin, and Y = 0.0763X + 0.0139 ( R 2 = 0.9993) for astragaloside IV, which indicated good linear relationships. The methodological investigation was stable, with the interday and intraday precision RSD
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- School of Minerals Processing and Bioengineering, Central South University, Changsha, China.
- Department of Ultrasound, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Psychiatry, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
ORCID-Profile: Lin Zhou
Förderung
- Key scientific research Project of colleges and universities in Henan Province
- Henan Province Science and Technology Research Project
- Medical Science and Technology Project of Henan Province
- National Natural Science Foundation of China
Zitieren
APA
Zhou, L., Wang, X., Xia, J., Zhang, L., Xue, L., Jia, Q., Fu, Z., & Sun, Z. (2023). Pharmacokinetic–pharmacodynamic modeling of the active components of Shenkang injection in rats with chronic renal failure and its protective effect on damaged renal cells. Biopharmaceutics & Drug Disposition. https://doi.org/10.1002/bdd.2377
Vancouver
Zhou L, Wang X, Xia J, Zhang L, Xue L, Jia Q, et al. Pharmacokinetic–pharmacodynamic modeling of the active components of Shenkang injection in rats with chronic renal failure and its protective effect on damaged renal cells. Biopharmaceutics & Drug Disposition. 2023. doi:10.1002/bdd.2377
BibTeX
@article{Zhou2023,
author = {Zhou, Lin and Wang, Xiaohui and Xia, Jinlan and Zhang, Liyuan and Xue, Lianping and Jia, Qingquan and Fu, Zhihui and Sun, Zhi},
title = {Pharmacokinetic–pharmacodynamic modeling of the active components of Shenkang injection in rats with chronic renal failure and its protective effect on damaged renal cells},
journal = {Biopharmaceutics & Drug Disposition},
year = {2023},
doi = {10.1002/bdd.2377}
}
EUVIMED